 |
|
|
| |
COMPASSIONATE USE OF LONG-ACTING (LA) CABOTEGRAVIR (CAB) AND RILPIVIRINE (RPV) FOR PATIENTS IN NEED OF PARENTERAL ANTIRETROVIRAL THERAPY
|
| |
| |
IAC 2020 July 6-10 Virtual
Reported by Jules Levin
Ronald D'Amico,1 Riya Moodley,2 Erika van Landuyt,3 Rodica Van Solingen-Ristea,3 Bryan Baugh,4 Veerle Van Eygen,3 Sherene Min,1 Annemiek de Ruiter,2
Amy Cutrell,1 Mark Shaefer,1 Caroline Foster,5 Daniella Chilton,6 Sabine Allard,7 David Margolis1
1ViiV Healthcare, Research Triangle Park, NC, USA; 2ViiV Healthcare, Brentford, UK; 3Janssen Pharmaceutica, Beerse, Belgium; 4Janssen Pharmaceutica, Raritan, NJ, USA; 5Imperial College NHS Healthcare Trust, London, UK; 6Guys and St Thomas NHS Healthcare Trust, London, UK; 7HIV Reference Center Universitaire Ziekenhuis Brussel, Brussels, Belgium
|
| |
|
|
|
|
|
